Compliance for skin-contact finished goods supplied into the EU shifts on Regulation (EC) No 1223/2009. N-Acetyl-L-lysine (CAS 1946-82-3) is not listed in Annex II, Annex III, Annex IV, Annex V, or Annex VI as scheduled for a specific cosmetic concentration. The substance is aligned with Article 3 safety assessment frameworks and Annex I dossier construction when export documentation is prepared for EU Responsible Persons. CosIng identifies Acetyl Lysine as the INCI name with a skin conditioning function, but no Annex III concentration cap applies. In a representative O/W leave-on emulsion, addition of the powder is performed in the aqueous phase after initial demineralized water heating to 40–45 °C. The dissolved stream is adjusted to pH 5.5–6.0 with citric acid or sodium hydroxide solution because the amide bond becomes less stable at pH values above 9.0 and below 2.0 under elevated temperature. A high-shear homogenizer, such as a Silverson L5T with an axial flow head at 3,000–5,000 rpm, is used after the oil phase is added at 75–80 °C to form the primary emulsion, but the N-acetyl-L-lysine water stream is introduced after bulk cool-down to 45 °C to avoid prolonged heat exposure. In a typical aliphatic ester oil phase with glyceryl stearate/PEG-100 stearate emulsifier, the addition level is 0.1–1.0 wt%; the lower end is used in clear or low-viscosity serums and the upper end in rich creamy emulsions with higher buffering capacity and lower sensitivity to pH drift. The finished formulation is monitored at pH 5.8–6.3 and viscosity 15,000–35,000 mPa·s as measured on a Brookfield LV viscometer with spindle 64 at 12 rpm and 25 °C. Terminal products include moisturizing face creams, post-procedure emulsions, and night recovery serums. Because published formulation data for this specific composition are limited, the addition ratio is established by the product's own stability protocol rather than by a regulatory concentration cap.

Production-scale batches on an in-line mixing line with a 300 L vacuum vessel and bottom-mounted homogenizer show that pre-dissolution eliminates batch-to-batch variation in clarity, but there is a processing boundary: direct powder addition to the cooled emulsion causes localized amine interaction around the anionic acrylic polymer network. If the system is a carbomer-based gel, neutralization order is critical. Triethanolamine or sodium hydroxide should neutralize the carbomer before N-acetyl-L-lysine addition to prevent ionic competition and reversible viscosity collapse. At addition ratios above 1.0 wt%, a shift in the neutralization pool is possible, and final pH can drift by 0.2–0.3 pH units during aging at 40 °C/75 % RH for twelve weeks. Therefore, the product is restricted to systems that maintain buffer capacity above 20 ± 5 mmol/L acetate or citrate equivalent. The material is specified with loss on drying ≤0.5 % and residue on ignition ≤0.1 % in the supplier certificate of analysis. Microbiological integrity is assessed under ISO 11930:2019 challenge testing when the finished product is not classified as low-risk under ISO 29621:2017.

What Are the Stoichiometric Boundaries in Solution-Phase Peptide Capping with Nα-Acetyl-L-Lysine?

Pharmaceutical intermediate applications use Nα-acetyl-L-lysine when a free ε-amino is required for chemoselective coupling while the α-amino is already blocked. The downstream process is typically a solution-phase carbodiimide-mediated coupling in anhydrous N,N-dimethylformamide or dichloromethane at 0–4 °C. The carboxyl component is activated with 1.0–1.2 mol equivalents of N,N'-diisopropylcarbodiimide or N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 0.5–1.0 mol equivalent of hydroxybenzotriazole or 7-aza-1-hydroxybenzotriazole. The Nα-acetyl-L-lysine free ε-amino is introduced at a molar ratio of 1.0:1.0 to 1.1:1.0 relative to the activated carboxyl component. Reaction progress is followed by thin-layer chromatography or liquid chromatography-mass spectrometry at 210–220 nm. The terminal products are N-terminal acetylated peptide analogues, peptide-biomolecule conjugates, and acylated peptide intermediates for drug substance development. The relevant compliance framework is ICH Q7 for active pharmaceutical ingredient GMP when the peptide is routed to clinical manufacturing; residual solvent levels are controlled per ICH Q3C, USP General Chapter <467>, and Ph. Eur. 5.4. Elemental impurities are evaluated with ICH Q3D using USP <232>/<233> or Ph. Eur. 2.4.20 if the material is sourced for cGMP batches. Published conversion data for this exact building block in solution-phase capping reactions are limited; therefore process development batches define coupling efficiency and impurity purge. Coupling efficiency is confirmed on a per-campaign basis because the ε-amine of the acetylated lysine can be less reactive in hindered sequences, and over-acylation is controlled by maintaining the internal temperature below 5 °C during the first 4 hours. The powder is pre-dried under vacuum at 30–35 °C for 12–24 hours to remove free water before anhydrous coupling; water content above 0.5 % can consume the carbodiimide and reduce the isolated yield.

On a 10 L jacketed glass reactor with nitrogen sparging and a Teflon-coated thermal probe, the washed solid is isolated by cold methyl tert-butyl ether precipitation or silica plug filtration depending on the peptide sequence. Batch-to-batch variance arises mostly from residual solvent in the starting powder: if the material is not subjected to controlled vacuum drying, the first coupling can stall at 60–70 % conversion after 12 h. The isolated product is released against a specification that includes chromatographic purity ≥98.0 % by area normalization at 210 nm, residual DMF ≤880 ppm, and residual methylene chloride ≤600 ppm consistent with ICH Q3C Class 2 limits.

Rinse-off hair conditioning systems place N-acetyl-L-lysine in a low-pH post-emulsification zone because surfactant clearing temperatures and citric acid chelation cycles reduce the free ε-amino availability. The powder is dissolved separately in demineralized water at 25–30 °C and adjusted to pH 4.5–5.0; the solution is metered into the cooled bulk after the quaternary ammonium emulsifier has formed its lamellar gel-network at 45–50 °C. Addition level in this product format is 0.2–0.5 wt%, with the lower boundary set by the limit of quantitation for the amino acid derivative in the finished emulsion and the upper boundary set by cationic surfactant charge-density variation. The production process on side-scraper mixing vessels is deliberately kept at ≤80 rpm during cool-down to avoid shear-thinning the behenyltrimonium chloride/cetearyl alcohol network. Terminal finished goods include post-colour masks, rinse-off conditioners, and scalp tonic emulsions. The relevant compliance standard is ISO 22716:2007 for cosmetic GMP; the material is assessed under Regulation (EC) No 1223/2009 Annex I Part A for physicochemical and chemical properties. Because the rinse-off form is briefly in contact with scalp tissue, the safety dossier must include dermal irritation data under OECD 439 or existing first-generation toxicological data as applicable. No standardized industry-wide addition table exists for this parameter; pilot trials under controlled temperature and humidity determine the locked range. In anionic cleansing systems with sodium C14-16 olefin sulfonate, the N-acetyl-L-lysine solution is added after sodium chloride thickener to prevent prolonged interaction with free sulfonic acid intermediates.

Production-scale failure modes appear when propylene glycol is used as a pre-solvent instead of water: the amino acid derivative settles on the tank wall if the glycol phase is below 15 °C, leading to particle count increase in the finished conditioner. For this reason, water-phase pre-dispersion remains the standard process, and the pre-solvent line is flushed with water at 35 °C for 5 minutes after injection. At addition levels below 0.1 wt%, the material is not analytically resolvable from the base vehicle in routine HPLC-UV after standard dilution; batch records with automated gravimetric dosing should have a dosing tolerance not exceeding ±0.02 wt%.

When N-Acetyl-L-Lysine Is Compounded as an Aminoacylase I Substrate in Aqueous Reagent Systems

Aqueous diagnostic reagent compounding uses N-acetyl-L-lysine as a substrate for aminoacylase I (EC 3.5.1.14) where deacetylation releases L-lysine and acetate. The substrate solution is prepared in 100 mM sodium phosphate buffer, pH 7.2–7.4, at a working concentration of 5.0 mM, with a concentration range of 2.0–10.0 mM depending on detection chemistry. The solution is filtered through a 0.22 µm polyethersulfone membrane and stored at 2–8 °C for not more than 72 h because hydrolytic release of free lysine in aqueous buffer can occur at a slow rate even without enzyme. The relevant specification is enzymatic purity, expressed as a substrate blank absorbance below 0.050 AU at 280 nm after the reagent blank is subtracted. Downstream production of liquid ready-to-use kits uses lyophilized substrate pellets or liquid-stable separation reservoirs; where lyophilization is applied, N-acetyl-L-lysine is pre-dosed at 5.0 ± 0.1 mg per vial before freeze-drying at −40 °C for 48 ± 4 h. Terminal finished goods are acylase activity assay kits, enzyme quality control reagents, and enzyme activity verification standards. The compliance framework is ISO 13485:2016 when the reagent is sold as a component of an IVD system under Regulation (EU) 2017/746; where supplied as a research biochemical, the certificate of analysis is aligned with reagent-grade or peptide-grade testing.

For shipment under tropical conditions, dissolution testing at 30 °C/65 % RH for 14 days is used to detect premature hydrolytic release. Liquid substrate reservoirs should not be frozen to −20 °C, as freeze-thaw cycles can produce precipitate that blocks the 0.22 µm filter in automated analysers. If frozen transport is unavoidable, the receiving laboratory is directed to thaw at 4 °C for 24 h and mix by gentle rotation at 10 rpm before use. The lyophilized cake is checked for collapse or meltback by visual inspection and by Karl Fischer water content ≤2.0 %; vials that exceed this specification show lower substrate recovery due to localized freeze-concentration of the amino acid. Free L-lysine impurity levels in the substrate vial are controlled at ≤0.5 % by peak area to prevent inflated blank rates in kinetic detection systems.